Eli Lilly's Tirzepatide: Weight Loss Wonder or Muscle Mass Menace?

A recent study highlights that Eli Lilly's GLP-1 drug, tirzepatide, delivers more significant weight loss than Novo Nordisk's semaglutide. However, it comes at the cost of greater muscle mass and connective tissue loss, raising concerns among healthcare professionals.

The analysis, conducted by nference, involved around 1,800 tirzepatide users and 6,200 semaglutide users. Results indicated that tirzepatide was linked to a more considerable reduction in lean body mass compared to semaglutide, raising questions about the drug’s long-term impact on patient health.

Despite these findings, there is no clear explanation for the increased lean body mass loss with tirzepatide. Novo Nordisk and Eli Lilly offered differing perspectives, with Novo maintaining that muscle mass changes were not significant when compared with placebo, while Eli Lilly compared the effects to those seen with traditional weight loss methods.